Inclusion Criteria:

- Histologic diagnosis of nasopharyngeal carcinoma or NSCLC

- With an evaluable secondary malignant neoplasm of Liver, diameter≥2cm

- Without transcatheter arterial chemoembolization (TACE) treatment

- Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.

- Estimated life expectancy of at least 3 months

- Patient compliance and geographic proximity that allow adequate follow-up.

- Adequate organ function including the following: Bone marrow: absolute neutrophil
count (ANC) >or= 1.5x10^9/L, platelets >or= 100x10^9/L, hemoglobin >or= 9g/dL.
Hepatic: bilirubin <1.5 x ULN, alkaline phosphatase, aspartate transaminase (AST) and
alanine transaminase (ALT) < 2.5 x ULN (alkaline phosphatase, AST, ALT < 5 x ULN is
acceptable if liver has tumor involvement). Renal: calculated creatinine clearance >
45 ml/min.

- Men or women of at least 18 years of age.

- Signed informed consent from patient.

Exclusion Criteria:

- Women who are pregnant or in lactation

- Systemic treatment for another cancer within the year prior to study entry

- Known hypersensitivity to any of the study drugs or to drugs with similar chemical
structures

- Use of investigational agents within 28 days of the Baseline visit, or participating
simultaneously in any other clinical studies

- Severe co-morbidity of any type that may interfere with assessment of the patient for
the study